Valneva unveils two recent EB66 agreements
Valneva has already signed a total of seven new deals for EB66, a pandemic flu vaccine, since the start of 2015. The company expects that it will sign even more agreements throughout the second half of this year.
All of the license agreements are solely dedicated to the company’s new EB66 cell line, which is for veterinary and human vaccines that are currently under development.
Valneva officials have reported that they estimate Kaketsuken to be the first that will earn a stockpiling contract for the new vaccine.
"The EB66 cell line has proven its performance in the development of both veterinary and human vaccines with the marketing approval of three new EB66-based vaccines in 2014 in three different regions of the world at a time when the regulatory environment is very demanding,” President and CEO Thomas Lingelbach and Valneva Deputy CEO Franck Grimaud said. “The industry is becoming increasingly aware that the half-century-old egg-based method of producing vaccines has major limitations and some of the world's largest pharmaceutical companies have already found in Valneva's EB66 technology an excellent replacement for egg-based vaccine production."